Pharmacy Billing Services · 2026

DIR reform moved the money to the counter. 340B and NADAC decide who keeps it.

Since CMS pushed all Part D pharmacy price concessions to the point of sale, the "clawback" you used to eat months later now shows up in the negotiated price on day one. Layer 340B modifiers and 50 different NADAC-based Medicaid rates on top, and the same fill pays very differently depending on the map pin.

Short answer: Bill 2026 pharmacy claims to the new reality, not the old one. Retail price concessions are now applied at the point of sale under the CMS Part D final rule, so reconcile against the negotiated price, not a year-end DIR true-up. Flag 340B-acquired drugs with the correct identifier for the payer (Medicare OPPS uses JG and TB; most state Medicaid programs use their own 340B indicator). And price every Medicaid fill off that state's NADAC plus its professional dispensing fee, because both diverge sharply state to state.

The shift in one screen

Three moving parts, one claim

Each of these is a real, named 2026 policy lever. Get one wrong and the fill still adjudicates, it just adjudicates against you.

POS

Part D price concessions now applied at the point of sale, not retrospectively as year-end DIR (CMS-4201-F).

JG / TB

The two Medicare OPPS 340B modifiers: JG identifies the 340B-acquired drug, TB is the informational flag for exempt providers.

NADAC

CMS survey benchmark, refreshed weekly on Medicaid.gov, that most states use as the acquisition-cost basis for FFS pharmacy.

50+DC

Professional dispensing fees are set per state from cost-of-dispensing surveys, so the "plus" on NADAC is never the same twice.

The state-by-state reality

Same NADAC, different paycheck

NADAC is a national number. What a pharmacy actually collects from Medicaid is NADAC plus that state's professional dispensing fee, and states land in very different places on that fee. The tiles below are grouped by relative dispensing-fee posture, not exact dollars. Hover any state.

RELATIVE MEDICAID PROFESSIONAL DISPENSING FEE POSTURE

Lean Mid Higher Cost-study driven high Illustrative

WANADAC+DFFee-schedule states post their AAC basis and dispensing fee in the pharmacy provider manual. Reconcile every fill to it.

ORNADACMany western states peg FFS to NADAC as actual acquisition cost per the Covered Outpatient Drug rule.

CAAAC+DFLarge-program states run their own AAC survey feeding a state-specific dispensing fee. Do not assume the national NADAC fee.

AZCost studyCost-of-dispensing surveys can push a state's professional dispensing fee well above its neighbors on the same NADAC.

NVNADACNeighboring states can share a NADAC basis yet pay a different dispensing fee. The pin, not the drug, moves the money.

COCost studyCost-study states publish a higher professional dispensing fee to reflect rural and independent pharmacy realities.

NMAAC+DFConfirm the exact dispensing fee tier in the state manual, some states tier by generic vs brand or by volume.

TXNADACHigh-volume Medicaid states still price FFS off NADAC, so a weekly NADAC refresh directly changes ingredient cost.

OKAAC+DFReconcile ingredient cost to the current week's NADAC file, stale pricing is a top pharmacy denial and takeback driver.

LACost studySouthern cost-study states can carry a materially higher dispensing fee, protect it by billing the correct fee, not a default.

MNNADACManaged-care carve-in vs FFS changes which pricing logic applies, verify the member's benefit first.

WIAAC+DF340B claims to Medicaid must not exceed actual acquisition cost, the anti-duplicate-discount rule still governs.

MINADACMany states require a 340B indicator on the Medicaid claim so the drug is excluded from the manufacturer rebate file.

OHAAC+DFSingle-PBM and transparent-pass-through states have reshaped dispensing economics, read the current manual.

PANADACNortheast states vary widely on dispensing fee, do not port one state's fee assumption to the next.

NYAAC+DFLarge programs periodically re-survey cost of dispensing, a mid-year fee change can move margin overnight.

VTCost studyRural-heavy states often set the highest dispensing fees to keep independents solvent.

GANADACConfirm whether the plan is FFS or MCO, the pricing floor and the 340B handling can both differ.

FLAAC+DFHigh-volume southern states, watch NADAC refresh timing against your submission date.

SCCost studyCost-study fee plus current NADAC is the collectible amount, bill both accurately or leave money on the counter.

Tile placement and shading are illustrative groupings of relative dispensing-fee posture, not exact per-state dollar amounts. Every reimbursement decision must be verified against the state's current Medicaid pharmacy provider manual and the current weekly NADAC file on Medicaid.gov. The point stands regardless of the exact figures: on identical NADAC, the collectible amount changes with the state's professional dispensing fee.

How we got here

DIR reform, in the order it hit your claims

1Before reform

Retrospective DIR clawbacks

Part D pharmacy price concessions were assessed weeks or months after the fill. Pharmacies booked a gross reimbursement, then absorbed a later takeback they could not predict at the counter.

2CMS final rule

Point-of-sale application required

The CMS Contract Year 2024 Part D final rule (CMS-4201-F) requires plans to apply all pharmacy price concessions to the negotiated price at the point of sale, redefining "negotiated price" as the lowest amount the pharmacy could receive.

32024 transition

The one-time cash-flow trough

Because old-model clawbacks and new-model lower up-front prices briefly overlapped, pharmacies felt a documented transition-year cash-flow dip. The steady state is lower gross per fill, but no surprise retro clawback.

42025 to 2026 steady state

Reconcile to the negotiated price

In 2026 the discipline is different: match remittance to the point-of-sale negotiated price, not to an expected year-end DIR reconciliation. Variance work moves upstream to adjudication, not the annual true-up.

340B on the claim

Which 340B flag, and where

The 340B identifier is payer-specific. Using the Medicare OPPS modifier on a Medicaid claim, or skipping the state 340B indicator, is how a compliant fill turns into a duplicate-discount problem.

Medicare OPPS: 340B-acquired drug

Appended to identify a drug purchased under the 340B program on outpatient hospital claims subject to the OPPS payment methodology.

USE: hospital outpatient (OPPS), 340B-purchased separately payable drugs

Medicare OPPS: informational 340B flag

The informational counterpart used by providers exempt from the 340B payment adjustment (for example rural sole community and certain cancer / children's hospitals) to flag 340B acquisition without the payment reduction.

USE: exempt / rural providers reporting 340B acquisition informationally

MCD

State Medicaid: the state's own 340B indicator

Medicaid claims for 340B drugs must not exceed actual acquisition cost and must be identified so the drug is excluded from the manufacturer rebate file. Many states require a 340B indicator (commonly a claim-level flag or a modifier such as UD); the exact convention is set by each state manual.

USE: per the state's pharmacy / 340B billing manual, prevents duplicate discount

Field reference

What changes by payer lane

Lane	Pricing basis	340B identification	2026 watch-out
Medicare Part D (retail)	Point-of-sale negotiated price after all concessions CMS-4201-F	Not JG/TB (those are OPPS); handled in Part D contracting	Reconcile to POS price, not a year-end DIR true-up
Medicare hospital outpatient	OPPS payment methodology	JG on 340B drugs; TB for exempt providers	Correct modifier per provider type and exemption status
Medicaid FFS	Actual acquisition cost, commonly NADAC, plus state professional dispensing fee COD rule	State-specific 340B indicator; never exceed actual acquisition cost	Use the current weekly NADAC and the correct state fee
Medicaid managed care	Plan / PBM logic, often anchored to the state benchmark	Follow the state and plan 340B billing rules	Confirm FFS vs MCO carve status before pricing the fill

Why two identical fills pay differently

The divergence, made concrete

Same drug, State A

NADAC-based ingredient cost plus a lean professional dispensing fee. Thin per-fill margin means NADAC refresh timing and clean 340B flags decide whether the fill is profitable at all.

Ingredient (NADAC) + lean DF = tight

Same drug, State B

Identical NADAC, but a cost-study-driven professional dispensing fee. The collectible amount is meaningfully higher for the exact same NDC and quantity, purely because of the state fee.

Ingredient (NADAC) + cost-study DF = higher

Bill every state like it is its own country. Because for pharmacy, it is.

ASP-RCM Solutions runs pharmacy billing against the current NADAC file, each state's professional dispensing fee, and the exact 340B identification each payer lane requires, with point-of-sale reconciliation built for the post-DIR world. Fewer takebacks, cleaner 340B compliance, and margin you actually keep.

Talk to our pharmacy billing team

Senior Partner, ASP-RCM Solutions · Frisco

Sources cited by name:

CMS Contract Year 2024 Medicare Advantage and Part D final rule (CMS-4201-F), point-of-sale application of pharmacy price concessions and the redefined negotiated price.
Medicare OPPS 340B claim modifiers JG (340B-acquired drug) and TB (informational flag for adjustment-exempt providers).
CMS Covered Outpatient Drug final rule, actual acquisition cost plus professional dispensing fee framework for Medicaid FFS pharmacy.
NADAC (National Average Drug Acquisition Cost), CMS survey benchmark published weekly on Medicaid.gov, and state-specific professional dispensing fees derived from state cost-of-dispensing surveys.

Verify every figure against the current NADAC file and the applicable state Medicaid pharmacy provider manual before billing.